Pinealon and Vilon: Bioregulator Peptides in Longevity Research

The Khavinson Bioregulator Framework

The Khavinson bioregulator framework — developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology — proposes that short synthetic peptides (typically 2 to 4 amino acids) regulate tissue-specific gene expression via direct DNA binding. The framework distinguishes bioregulators from classical receptor-binding pharmacology by their minimal size and proposed chromatin-interaction mechanism. The Advanced Peptide Science catalogue stocks three Khavinson bioregulators: the tetrapeptide Epitalon (telomerase research), the tripeptide Pinealon (CNS neuroprotection), and the dipeptide Vilon (thymic-immune). The size-activity series enables research-tool comparison of bioregulator structure-function relationships.

Pinealon: Tripeptide Glu-Asp-Arg

Pinealon is a synthetic tripeptide bioregulator with sequence Glu-Asp-Arg (EDR) and molecular weight 417.4 Da. The compound was developed from pineal-gland research within the Khavinson framework — focused specifically on CNS neuroprotection applications rather than telomerase or thymic research. Research investigates neuroprotective signalling in CNS preclinical models, epigenetic regulation in neural cell lines, circadian rhythm pathway modulation, and BDNF and neurotrophic factor expression effects.

Vilon: Dipeptide Lys-Glu (the Minimum Bioregulator)

Vilon is a synthetic dipeptide bioregulator with sequence Lys-Glu (KE) and molecular weight 275.3 Da — the smallest member of the Khavinson framework. The compound was derived from thymic-tissue research, with research applications focused on thymic function restoration, immune senescence pathway modulation, telomere length in lymphocyte preclinical models, and cellular regeneration mechanisms in ageing research contexts. The extreme simplicity (just two amino acids) makes Vilon a fundamental research tool for investigating bioregulator structure-activity minimal requirements.

Mechanism Hypothesis: Direct DNA Binding

The Khavinson framework proposes that bioregulator peptides directly bind specific DNA sequences in gene regulatory regions, modulating transcription factor binding or chromatin accessibility. Mechanism research investigates whether short peptides can achieve sequence-specific DNA binding analogous to transcription factor recognition motifs, and whether such binding produces tissue-specific gene expression effects consistent with the framework’s hypotheses. The framework remains an area of active research investigation distinct from classical receptor-binding pharmacology approaches.

Key Research Findings: Size-Activity Comparisons

Tripeptide vs Dipeptide Comparison

The Pinealon (tripeptide) vs Vilon (dipeptide) pair enables direct comparison of three-residue vs two-residue bioregulator activity. Different tissue specificity (CNS vs thymus) supports the framework’s tissue-specific gene-expression hypothesis, while structural minimalism provides a research-tool framework for fundamental bioregulator size-activity research.

Tetrapeptide Extension via Epitalon

Adding Epitalon (tetrapeptide AEDG, pineal-derived) to the comparison enables four-residue investigation — extending the size-activity research framework to the upper end of the bioregulator size range.

Comparative Bioregulator Pharmacology

Research comparing the three compounds (Vilon dipeptide, Pinealon tripeptide, Epitalon tetrapeptide) investigates whether the bioregulator framework’s proposed mechanisms scale with peptide size, whether tissue specificity changes with size, and whether the framework’s broader hypotheses are supported across the structural series.

Research Applications

Pinealon and Vilon are research tools for investigating the Khavinson bioregulator framework — including CNS neuroprotection (Pinealon), thymic-immune research (Vilon), comparative size-activity studies, and broader epigenetic-regulation hypothesis testing. Within the Longevity & Immune Support category, the bioregulator series complements mitochondrial-derived peptides MOTS-c and Humanin, the mitochondrial-targeted SS-31, and the senolytic FOXO4-DRI for comprehensive longevity research frameworks.

Research Specifications

Pinealon	417.4 Da, Glu-Asp-Arg (EDR) tripeptide, CNS neuroprotection focus
Vilon	275.3 Da, Lys-Glu (KE) dipeptide, thymic-immune focus
Framework	Khavinson bioregulator (proposed direct DNA binding mechanism)
Related Compounds	Epitalon (tetrapeptide AEDG, telomerase focus)
Format	Lyophilized powder in sterile vials
Purity	≥ 99% (HPLC verified)
Storage	-20 °C, protect from light

Frequently Asked Questions

What is the Khavinson bioregulator framework?

A research framework proposing that short synthetic peptides (2-4 amino acids) regulate tissue-specific gene expression via direct DNA binding — distinct from classical receptor-binding pharmacology. The framework was developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation.

How do Pinealon and Vilon differ in research applications?

Pinealon (tripeptide EDR, pineal-derived) focuses on CNS neuroprotection research. Vilon (dipeptide KE, thymic-derived) focuses on thymic-immune and lymphocyte research. The tissue-specific focus reflects the bioregulator framework’s tissue-specificity hypothesis.

How does this series compare to Epitalon?

Epitalon (tetrapeptide AEDG, pineal-derived) is the four-residue member of the same Khavinson framework, focused on telomerase research. Together with Pinealon (tripeptide) and Vilon (dipeptide), Epitalon forms a structural size-activity research series.

Are these compounds approved for human use?

Advanced Peptide Science supplies both bioregulator compounds exclusively for in vitro and in vivo scientific research. Not for human consumption. Research use only.

---

For Research Use Only. Not for human consumption. Not intended to diagnose, treat, cure, or prevent any disease.